Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 744 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Marizomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
Interventions
medrol dosepak, HYDROcodone Oral Tablet
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Conditions
Knee Arthritis
Interventions
Methylprednisolone, Standard of Care
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Tucker, Georgia
Active, not recruiting Phase 2 Interventional Results available

KRDI in Transplant-Eligible MM

NCT04430894
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8
Interventions
Cyclophosphamide, Dexamethasone
Drug
Lead sponsor
Rashmi Verma, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Sacramento, California
Conditions
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions
Inobrodib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • San Francisco, California • Jacksonville, Florida + 18 more
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
Oral sodium suppression test, Saline suppression test, Captopril suppression test, Dexamethasone suppression test, Cosyntropin stimulation test
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Gastroesophageal Cancer
Interventions
Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel, Rescue medications, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Gilbert, Arizona • Los Angeles, California • Orlando, Florida + 13 more
Active, not recruiting Phase 1 Interventional

Venetoclax Plus Inotuzumab for B-ALL

NCT05016947
Conditions
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL
Interventions
Venetoclax, Dexamethasone, Inotuzumab Ozogamicin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, prednisone, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
1,970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 24 more
Conditions
Multiple Myeloma
Interventions
Velcade, Cyclophosphamide, Revlimid
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Results available

Emend for Multiple-day Emetogenic Chemotherapy

NCT00711555
Conditions
Nausea, Vomiting
Interventions
aprepitant, ondansetron, dexamethasone
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting

NCT01474915
Conditions
Postoperative Nausea and Vomiting (PONV), Nausea
Interventions
Aprepitant, Ondansetron, Promethazine, Dexamethasone
Drug
Lead sponsor
Sergio Bergese
Other
Eligibility
18 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Oncologic Complications, Quality of Life, Nutrition Poor, Head and Neck Cancer, Lung Cancer, Pancreatic Cancer
Interventions
Dexamethasone, Dronabinol, Mirtazapine, Nutrition Intervention
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Multiple Myeloma
Interventions
LBH589, Lenalidomide
Drug · Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • New York, New York
Completed Phase 2 Interventional Results available

Ixazomib Rollover Study

NCT02924272
Conditions
Multiple Myeloma, Lymphoma, Amyloidosis
Interventions
Ixazomib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
4
States / cities
Atlanta, Georgia • Hazard, Kentucky • Boston, Massachusetts + 1 more
Conditions
Lymphoma
Interventions
Amifostine, DHAP
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Plasma Cell Myeloma
Interventions
Isatuximab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Plantation, Florida • Boston, Massachusetts
Conditions
Pain, Postoperative
Interventions
Dexamethasone, Analgesics
Drug
Lead sponsor
Duke University
Other
Eligibility
4 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Pneumonia
Interventions
Dexamethasone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 16 more
Conditions
Multiple Myeloma, Acute Myeloid Leukemia, Non-Hodgkins Lymphoma, Myelodysplastic Syndrome, AML, MDS, NHL
Interventions
AMG 397, Dexamethasone, Azacitidine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 9 more
Active, not recruiting Phase 1Phase 2 Interventional Results available

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

NCT05192889
Conditions
Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions
Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Dasatinib, Cytarabine, Blinatumomab, Methotrexate, Mercaptopurine, Cyclophosphamide, Etoposide, Leucovorin, Intrathecal Triples, Pegaspargase, Erwinia asparaginase, Radiation
Drug · Biological · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
4 Years to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Memphis, Tennessee
Conditions
Hematological Malignancy
Interventions
Isatuximab SAR650984, Dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2023
U.S. locations
16
States / cities
Scottsdale, Arizona • San Francisco, California • Atlanta, Georgia + 13 more